NIFUROXAZIDE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C12H9N3O5
Molecular Weight	275.217
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC1=CC=C(C=C1)C(=O)N\N=C\C2=CC=C(O2)[N+]([O-])=O

InChI

InChIKey=YCWSUKQGVSGXJO-NTUHNPAUSA-N

InChI=1S/C12H9N3O5/c16-9-3-1-8(2-4-9)12(17)14-13-7-10-5-6-11(20-10)15(18)19/h1-7,16H,(H,14,17)/b13-7+

HIDE SMILES / InChI

Molecular Formula	C12H9N3O5
Molecular Weight	275.217
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	1
Optical Activity	NONE

Description
Sources: https://www.moncoinsante.co.uk/ercefuryl-nifuroxazide-200-mg-sanofi-aventis-boite-de-12-gelules.html | https://www.ncbi.nlm.nih.gov/pubmed/18824601 | https://www.ncbi.nlm.nih.gov/pubmed/25811798 | https://www.ncbi.nlm.nih.gov/pubmed/26830149 | https://www.ncbi.nlm.nih.gov/pubmed/26154152 | https://www.ncbi.nlm.nih.gov/pubmed/28055016

Nifuroxazide is a nitrofuran antibiotic used for the treatment of acute infectious diarrhoea.Nifuroxazide is a potent inhibitor of Signal transducers and activators of transcription (STAT) signaling. It exerts antineoplastic potential both in vitro and in vivo.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Signal transducer and activator of transcription 3 10 Target ID: CHEMBL4026 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18824601	Inhibitor 8297		3.0 µM [EC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Cancer 592 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25811798 https://www.ncbi.nlm.nih.gov/pubmed/26830149 https://www.ncbi.nlm.nih.gov/pubmed/26154152 https://www.ncbi.nlm.nih.gov/pubmed/28055016	Primary		Preclinical	Unknown Approved Use Unknown
Infectious diarrhea 8 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7671647 https://www.ncbi.nlm.nih.gov/pubmed/2666238 https://www.ncbi.nlm.nih.gov/pubmed/28144199	Curative		Approved 8429	ERCEFURYL Approved Use Ercéfuryl Nifuroxazide 200 mg Capsules contain a gastro-intestinal antibiotic, nifuroxazide. They can be used to treat acute, infectious diarrhoea.

PubMed

Title	Date	PubMed
Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3.	2008 Dec 15	18824601

Patents

Sample Use Guides

In Vivo Use Guide

200 mg nifuroxazide 4 times a day in 2 to 4 doses.

Route of Administration: Oral

In Vitro Use Guide

2.5-20 uM nifuroxazide induces breast cancer cell apoptosis in a concentration-dependent manner.

Substance Class	Chemical Created by `admin` on `Sat Dec 16 15:54:29 GMT 2023` Edited by `admin` on `Sat Dec 16 15:54:29 GMT 2023`
Record UNII	PM5LI0P38J
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

NIFUROXAZIDE

Official Name

English

NIFUROXAZIDE [EP IMPURITY]

Common Name

English

NIFUROXAZIDE [MART.]

Common Name

English

Nifuroxazide [WHO-DD]

Common Name

English

NSC-759261

Code

English

NIFUROXAZIDE [EP MONOGRAPH]

Common Name

English

nifuroxazide [INN]

Common Name

English

P-HYDROXYBENZOIC ACID 5-NITROFURFURYLIDENE HYDRAZIDE

Common Name

English

SJ000287313

Code

English

RC-27109

Code

English

Classification Tree Code System Code

WHO-VATC

QA07AX03